Hospira has signed a business cooperation agreement with South Korea-based Celltrion for future distribution of biogeneric products in the U.S., Europe, Australia, New Zealand and Canada. Celltrion is currently developing eight biogeneric products, five of which relate to Hospira’s pipeline. The companies will collaborate on manufacturing and supply of the products. Following regulatory approval, Hospira and Celltrion will co-market the drugs, with the products independently commercial...